1. Clinical Overview
Acebrophylline is a bronchodilator and mucolytic agent, chemically a xanthine derivative. It is a complex of theophylline-7-acetic acid with ambroxol in a 2:1 molar ratio. It is widely used in India for the management of chronic obstructive pulmonary disease (COPD) and bronchial asthma, particularly when associated with excessive, viscous mucus. It acts by relaxing bronchial smooth muscle and reducing sputum viscosity, facilitating expectoration.
| Onset | Duration | Bioavailability |
|---|---|---|
| Within 30 to 60 minutes after oral administration. | Approximately 8 to 12 hours. | Approximately 70-80% after oral administration. |
2. Mechanism of Action
Acebrophylline exerts a dual action: 1) Bronchodilation via non-selective inhibition of phosphodiesterase (PDE) enzymes (PDE3, PDE4), leading to increased intracellular cyclic AMP (cAMP) in bronchial smooth muscle cells, causing relaxation. It may also antagonize adenosine receptors (A1 and A2). 2) Mucolytic action via its ambroxol component, which stimulates surfactant production, breaks down acid mucopolysaccharide fibers in sputum, and enhances ciliary activity, improving mucociliary clearance.
3. Indications & Uses
- Chronic Obstructive Pulmonary Disease (COPD) - maintenance therapy
- Bronchial Asthma - for relief of bronchospasm and associated mucus hypersecretion
4. Dosage & Administration
Adult Dosage: 100 mg (10 ml of 10 mg/ml solution) twice daily. May be adjusted based on severity and response. Typically administered after meals.
Administration: Oral solution should be measured with the provided measuring cup or syringe. Shake the bottle well before use. Can be taken with or after food to minimize gastric irritation. Maintain adequate fluid intake to help loosen mucus.
5. Side Effects
Common side effects may include:
- Nausea
- Epigastric discomfort/Heartburn
- Headache
- Mild dizziness
- Increased gastric acid secretion
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Ciprofloxacin/Levofloxacin | Markedly increases acebrophylline levels (CYP1A2 inhibition). Risk of toxicity. | Major |
| Phenytoin, Carbamazepine, Rifampicin | Decreases acebrophylline levels (CYP450 induction). May reduce efficacy. | Moderate |
| Cimetidine, Allopurinol | Increases acebrophylline levels (CYP450 inhibition). | Moderate |
| Beta-blockers (e.g., Propranolol) | Antagonistic effect; may reduce bronchodilator efficacy. | Moderate |
| Warfarin | Acebrophylline may potentiate anticoagulant effect. Monitor INR. | Moderate |
| Other Xanthines (Theophylline, Caffeine) | Additive toxicity (CNS, cardiac). | Major |
| Ketamine | Increased risk of seizures. | Major |
7. Patient Counselling
- DO take the medication exactly as prescribed, usually twice daily.
- DO take it after food if you experience stomach upset.
- DO maintain adequate fluid intake unless contraindicated.
- DO inform all your doctors and dentists you are taking this medicine.
- DO NOT crush or chew capsules if using that formulation; for solution, use proper measuring device.
- DO NOT increase the dose or frequency without consulting your doctor.
- DO NOT stop taking it abruptly if used for chronic conditions.
8. Toxicology & Storage
Overdose: Primarily extensions of its pharmacologic effects: Severe nausea, vomiting, hematemesis, tachycardia, cardiac arrhythmias (supraventricular & ventricular), hypotension, hyperglycemia, hypokalemia, agitation, tremors, seizures (often the first sign of serious toxicity), and eventual coma. Death is usually from ventricular arrhythmias or status epilepticus.
Storage: Store at room temperature (15-30°C). Protect from light and moisture. Keep the bottle tightly closed. Keep out of reach of children. Do not freeze the oral solution. Discard any unused medicine after the expiry date.